Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1143 plus Nivolumab in Advanced Solid Tumors
NCT04122625Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Apr 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of xevinapant in small cell lung cancer (SCLC), squamous cell carcinoma of the head and neck (HNSCC), gastrointestinal cancer and 4 more (6 arms), sponsored by Debiopharm. Primary endpoints: Dose-Limiting Toxicities and Confirmed Objective Response Rate up to 2.05 years. Started Apr 2019; status: completed.
02
Drugs
xevinapant
03
Conditions
small cell lung cancer (SCLC)squamous cell carcinoma of the head and neck (HNSCC)gastrointestinal cancerovarian epithelial cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04122625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122625.